Menopause Care Is Changing in 2026: What Clinics Should Know About Hormone Therapy Demand

Menopause care is entering a new phase. Patients are asking better-informed questions, clinical guidance is becoming more individualized, and recent regulatory developments are changing how hormone therapy is discussed.

For functional medicine and primary care clinics, the opportunity is significant: but so is the responsibility. A successful hormone replacement therapy (HRT) program requires thoughtful patient selection, shared decision-making, consistent monitoring, and a reliable pharmacy partner.

The demand is already visible in prescribing data.

Hormone therapy use has nearly doubled since 2017

A recent Epic Research analysis reviewed more than 163 million adult women seen in outpatient care between 2017 and April 2026.

The analysis found that hormone therapy use rose from approximately 1.7% of women in January 2017 to 3.6% in April 2026: a near doubling.

The increase was most pronounced among women in the typical menopause transition years:

• Hormone therapy use nearly tripled among women ages 45–54.
• Use also increased among women ages 35–44 and 55–64.
• Transdermal formulations, including patches and gels, grew faster than oral and injectable routes.
• Vaginal hormone therapy use also increased substantially.

These data do not mean every patient is an appropriate candidate for HRT. Epic used age as an approximate marker for menopause status, and the study measured outpatient prescribing patterns rather than total population use.

Still, the trend is important for clinics. More women are seeking symptom relief, more providers are revisiting the evidence, and menopause care is becoming a larger part of primary care and functional medicine practice.

What changed after the FDA’s late-2025 action?

In November 2025, the FDA initiated changes to the boxed warning language for menopausal hormone therapy products. In February 2026, the agency announced approval of labeling changes for an initial group of six products.

The changes removed boxed-warning language related to cardiovascular disease, breast cancer, and probable dementia from those products. The FDA’s updated communication also emphasized that treatment decisions should account for a patient’s age and the timing of therapy initiation.

This does not mean that hormone therapy is risk-free or appropriate for everyone. Relevant risks remain part of prescribing information, and clinicians must continue to evaluate medical history, contraindications, route of administration, treatment goals, and follow-up needs.

The FDA’s action is best understood as a shift away from one-size-fits-all messaging. It reinforces the importance of discussing absolute risks and benefits with each patient rather than relying on broad warnings that may not reflect the risk profile of a healthy woman beginning therapy near menopause.

Clinics should review the FDA’s updated prescribing information and the agency’s February 2026 announcement when updating patient education and internal protocols.

Patient preferences are influencing the conversation

Many patients are arriving with specific questions about hormone types and delivery methods. Two commonly discussed options are transdermal estradiol and micronized progesterone.

Transdermal estradiol

Transdermal estradiol is delivered through the skin by patch, gel, or another topical system. Compared with oral estrogen, transdermal therapy may be preferred for some patients because it bypasses first-pass hepatic metabolism.

Guidance from the NHS and other menopause organizations commonly identifies transdermal estrogen as an important option for patients with elevated venous thromboembolism risk, higher body mass index, migraine, or certain cardiovascular risk factors. The NHS Somerset transdermal HRT guidance provides a useful clinical overview.

The route should be selected based on the individual patient: not simply because it is currently popular. A clinic’s protocol should give prescribers a structured way to consider symptom severity, age, time since menopause, cardiovascular risk, clotting history, metabolic factors, and patient preference.

Micronized progesterone

For patients with an intact uterus who use systemic estrogen, an appropriate progestogen is generally needed to protect the endometrium.

Micronized progesterone is frequently discussed as an option because of its physiologic profile and its use in contemporary menopause care. However, the regimen, dose, timing, and route must be prescribed according to the patient’s clinical situation and current evidence.

The International Menopause Society’s 2025 recommendations emphasize individualized care, appropriate endometrial protection, and consideration of transdermal estrogen and micronized progesterone where clinically suitable.

Patients may also ask about compounded hormone preparations. Clinics should distinguish between FDA-approved therapies and compounded medications. Compounding may be appropriate for a specific patient when an approved product cannot meet a documented clinical need, but it should not replace careful diagnosis, informed consent, quality controls, and compliance with applicable laws and standards.

Shared decision-making should be the foundation

The updated menopause conversation is not about promising that HRT is universally safe. It is about helping an appropriate patient make an informed decision.

A strong consultation may include:

1. Clarifying the patient’s goals
   Ask which symptoms are most disruptive. Hot flashes, night sweats, sleep disruption, vaginal symptoms, mood changes, and quality-of-life concerns may require different approaches.

2. Reviewing the timing of therapy
   Many guidelines identify a more favorable benefit-risk profile for healthy women who are younger than 60 or within approximately 10 years of menopause onset. This is not an automatic approval criteria, but it is an important part of the discussion.

3. Assessing risk factors and contraindications
   Review personal and family history, breast and endometrial health, unexplained bleeding, cardiovascular disease, stroke, venous thromboembolism, liver disease, migraine, blood pressure, and other relevant conditions.

4. Discussing formulation and route
   Explain the differences between oral, transdermal, and local vaginal options. Patients should understand why a specific route is being recommended and what alternatives may exist.

5. Setting expectations for follow-up
   Establish how symptoms will be measured, when the patient will be reassessed, how bleeding or side effects will be addressed, and when the treatment plan may need to change.

6. Documenting the conversation
   Clear documentation supports continuity of care and demonstrates that the therapy was selected through an individualized, informed process.

The goal is not to follow a fixed “lowest dose for shortest time” formula without context. The goal is to use an appropriate treatment plan that is periodically reviewed as the patient’s symptoms, preferences, and health risks evolve.

What clinics should build into an HRT program

As demand grows, clinics may need more than a prescription template. They need a repeatable care pathway.

A practical menopause program may include:

• A standardized intake questionnaire
• A medication and contraindication review
• Baseline blood pressure, weight, and relevant health screening
• A documented shared decision-making workflow
• Clear criteria for referral or specialist consultation
• Defined follow-up intervals
• A process for managing side effects and unscheduled bleeding
• Patient education on administration, storage, and adherence
• A reliable medication fulfillment and communication process

Clinics should also make sure marketing claims are accurate. HRT should not be promoted as a general anti-aging treatment, weight-loss solution, or universal disease-prevention strategy. The clinical focus should remain symptom management, individualized risk assessment, and appropriate follow-up.

How a compounding pharmacy partner can support your clinic

A pharmacy partner can help reduce operational friction as your menopause program grows.

One Pharmacy can support clinics with:

• Prescription intake and clarification
• Coordination with prescribers and clinic staff
• Patient-specific compounded medications when clinically appropriate
• Consistent communication about refill timing and questions
• Packaging and dispensing workflows designed for recurring therapy
• Support for functional medicine, primary care, wellness, and telehealth practices
• A scalable process for clinics managing growing prescription volume

The pharmacy does not replace the prescriber’s clinical judgment. Instead, it helps the clinic execute the treatment plan accurately and consistently.

For any compounded medication, the prescription should be patient-specific, clinically justified, and prepared in accordance with applicable requirements. A strong pharmacy relationship also gives providers a resource for discussing dosage forms, availability, administration instructions, and patient adherence concerns.

Prepare for the next phase of menopause care

The rise in hormone therapy use is not simply a trend to watch. It is a signal that more patients are seeking informed, individualized menopause care: and that clinics need systems capable of delivering it safely.

Functional medicine and primary care practices are well positioned to meet this need because they already manage long-term relationships, preventive health, chronic conditions, and personalized treatment plans.

The clinics that stand out will be the ones that combine evidence-based prescribing with clear communication, careful documentation, reliable follow-up, and dependable pharmacy coordination.

If your clinic is building or expanding a menopause and HRT program, contact One Pharmacy to discuss how a pharmacy partner can support your prescribing workflow and patient care model.

Sources

• Epic Research: Hormone Therapy Use Nearly Doubled Since 2017
• FDA: FDA Approves Labeling Changes to Menopausal Hormone Therapy Products
• FDA: Updated Prescribing Information for Menopausal Hormone Therapies
• International Menopause Society: 2025 Recommendations
• NHS: Hormone Replacement Therapy
• NHS Somerset: Transdermal Hormone Replacement Therapy

This article is for professional education and does not replace clinical judgment, product labeling, applicable regulations, or individualized medical evaluation.